Lili Ding
6 Papers
Lili Ding is an academic researcher. The author has contributed to research in topics: Druggability & Chemistry. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
Jiawei Zhang,Yichao Gan,Hongzhi Qi,J. Yin,Xin He,Liming Lin,Senlin Xu,Zhipeng Fang,Byung-Wook Kim,Lina Gao,Lili Ding,Eryun Zhang,Xiaoxiao Ma,Junfeng Li,Ling Li,Yang Xu,David J. Horne,Rongzhen Xu,Hua Yu,Ying Gu,Wendong Huang +20 more
TL;DR: In this article , the authors identify two potential druggable pockets located in the protein-protein interaction interface (PPI) between CDK2 and cyclin A and demonstrate that homoharringtonine (HHT) shows high affinity to the PPI and strongly disrupts the interaction between the two proteins.
Red ginseng extracts ameliorate high-fat diet-induced obesity and insulin resistance by activating the intestinal TGR5-mediated bile acids signaling pathway.
Wei Li,Tongxi Zhuang,Zixuan Wang,Xunjiang Wang,Longchan Liu,Yi-nan Luo,Rufeng Wang,Linnan Li,Wendong Huang,Zhengtao Wang,Li Yang,Lili Ding +11 more
TL;DR: Red ginseng extracts treatment alleviated dietary-induced dyslipidemia and IR in obese mice in a dose-dependent manner and improved glucose and insulin tolerance, and energy expenditure and found that activating intestinal TGR5 facilitated the localization of ASBT to the plasma membrane, which ultimately promoted the transport of BAs to regulate metabolic phenotype.
17
CYP8B1 downregulation mediates the metabolic effects of vertical sleeve gastrectomy in mice.
Yanjun Liu,Jui Tu,Linsen Shi,Zhipeng Fang,Mingjie Fan,Jianying Zhang,Lili Ding,Yiqiang Chen,Yangmeng Wang,Eryun Zhang,Senlin Xu,Nisha Sharma,John D. Gillece,Lauren J Reining,Lihua Jin,Wendong Huang +15 more
TL;DR: Modulation of BA composition and GM profile by targeting CYP8B1 may provide novel insight into the development of therapies that non-invasively mimic bariatric surgery to treat obesity and its complications.
3
Pharmacology and therapeutics of bile acid synthesis and modification enzymes in metabolic diseases
Lili Ding,Wendong Huang +1 more
Abstract: Bile acids (BAs) are mainly synthesized in the liver as end products of cholesterol catabolism through the classic (neutral) and alternative (acidic) pathways. BA synthesis requires a coordinated series of enzymes, in which CYP7A1 catalyzes the rate-limiting step, whereas CYP8B1 determines the proportion of the 2 primary BAs-cholic acid and chenodeoxycholic acid. Enterohepatic circulation of BAs is essential not only for nutrient absorption but also for maintaining systemic metabolic homeostasis. The expanding catalog of BA-responsive receptors throughout the gastrointestinal tract and peripheral metabolic tissues underscores the hormone-like nature of BAs in metabolic regulation. Moreover, dynamic and bidirectional interactions between BAs and the gut microbiota introduce an additional layer of complexity that shapes physiological and pathological metabolic processes. Targeting BA synthesis and microbial modification offers substantial therapeutic potential for a wide spectrum of metabolism-related diseases. SIGNIFICANCE STATEMENT: Bile acids (BAs) comprise a large family of endogenous steroid metabolites with diverse chemical structures. They can activate or inhibit a panel of BA-responsive receptors to elicit distinct cellular signaling programs integral to metabolic regulation. Their reciprocal interactions with gut microbiota further amplify the complexity of host metabolic control. Therapeutic strategies that modulate BA synthesis and microbial BA transformation, leveraging both BA synthesis enzymes and microbial partners, hold great promise for treating metabolic disorders.
Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells
Jiawei Zhang,Yichao Gan,Hongzhi Qi,J. Yin,Xin He,Liming Lin,Senlin Xu,Zhipeng Fang,Byung-Wook Kim,Lina Gao,Lili Ding,Eryun Zhang,Xiaoxiao Ma,Junfeng Li,Ling Li,Yang Xu,David J. Horne,Rongzhen Xu,Hua Yu,Ying Gu,Wendong Huang +20 more
TL;DR: In this article , the authors identify two potential druggable pockets located in the protein-protein interaction interface (PPI) between CDK2 and cyclin A and demonstrate that homoharringtonine (HHT) shows high affinity to the PPI and strongly disrupts the interaction between the two proteins.